2 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 4 Phase 1, 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Terminated 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Not applicable | 2 | Recruiting 2 |
Follow Aggressive Lymphoma: new trials by email Literature Review of Aggressive Lymphoma trials Research Report on Aggressive Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma Early Palliative Care - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Not applicable | Recruiting | University Health Network, Toronto | 144 | 2024-07-18 | 2025-12-03 |
| Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma Al18F-NOTA-FAPI, Al18F-NOTA-grazytracer/68Ga-grazytracer - Aggressive Lymphoma | Not applicable | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 94 | 2024-07-11 | 2026-10-07 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers NKX019 - Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Nkarta, Inc. | 150 | 2021-08-20 | 2026-04-20 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| A Study Of The Selective PKC-β Inhibitor MS- 553 MS-553, acalabrutinib, venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 60 | 2018-05-25 | 2025-04-10 |
| Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma Bendamustine and subcutaneous rituximab - Aggressive Lymphoma | Phase 2 | Completed | University of Göttingen | 68 | 2012-07-04 | 2018-12-31 |
| Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL Rituximab, Gemcitabine, Oxaliplatin, Dexametasone - Aggressive Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 82 | 2011-04-01 | 2017-10-30 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Lymphoma, Non-Hodgkin (4) · Hematologic Diseases (3) · Lymphoma, B-Cell (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2)
Rituximab (2) · Bendamustine Hydrochloride (1) · Gemcitabine (1) · LFB-R603 (1) · Oxaliplatin (1) · acalabrutinib (1) · obinutuzumab (1) · ublituximab (1) · venetoclax (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · MingSight Pharmaceuticals, Inc (1) · Nkarta, Inc. (1) · TG Therapeutics, Inc. (1) · University Health Network, Toronto (1) · University of Göttingen (1) · Washington University School of Medicine (1)
United States (4) · Australia (1) · Canada (1) · China (1) · Germany (1) · Spain (1)
Armin Ghobadi, M.D. (1) · Breffni Hannon, MB BCh BAO, MMedSci, MCFP (1) · Carlos Grande, MD (1) · Carlos Panizo Santos, MD (1) · David Shook, MD (1) · Isidro Jarque, MD (1) · Javier Briones Meijide, MD (1) · Joan Bargay Leonart, MD (1) · Jorge Gayoso Cruz, MD (1)